MIT is pleased to announce the nomination of Mr. Jacques Gauthier and Mr. Michel Carrier to its newly formed Advisory Board
Mr. Jacques Gauthier has served on the board of directors of Axcan Pharma Inc. since 1995. He is currently an advisor to the President and Scientific Director at Montreal Clinical Research Institute. Mr. Gauthier also serves on the board of directors of a variety of medical and pharmaceutical companies and associations. He has held various senior management positions, both in Canada and abroad, with UpJohn Laboratories Inc. and UpJohn International Inc., currently owned by Pfizer. In 1984, Mr. Gauthier joined BioMega / Boehringer Ingelheim Research Inc. where he served as president and general manager until 1996.
Mr. Michel Carrier has held various senior management positions in marketing and sales over the past 25 years. His vast experience and innovative marketing methods make him a great asset as a member of MIT's Advisory Board.
MIT President and CEO, Mr. Karim Menassa, believes that the nomination and acceptance by Mr. Gauthier and Mr. Carrier is a very important and positive step for the immediate and future success of the company.
Medical International Technology Inc. is proud to continue providing a safe and effective means to help prevent the spread of deadly diseases to both humans and animals through the use of the Med-Jet(R) and Agro-Jet(R) needle-free injection system.
About Medical International Technology, Inc. MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations.
The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. Medical International Technology Inc. takes no obligation to update or correct forward-looking statements.
SOURCE MEDICAL INTERNATIONAL TECHNOLOGIES INC.
You May Also Like